Quality of life in patients with remitting-relapsing multiple sclerosis in Germany;Lebensqualität bei patienten mit schubförmiger MS in Deutschland

Nervenarzt

Volumn 74, Issue 2, 2003, Pages 144-150

  Haupts, M ^a   Elias, G ^b   Hardt, C ^c   Langenbahn, H ^d   Obert, H ^e   Pohlau D ^h   Sczesni, B ^f   Wussow, P V ^g  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b Neurol Schwerpunktpraxis Hamburg   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d MedPharmTec   (Germany)

^e Serono Pharma   (Germany)

^f Neurologische Praxis Bochum   (Germany)

^g UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^h Knappschafts Krankenhaus ^*

Author keywords

Multiple sclerosis; Quality of life; Responder; Therapy

Indexed keywords

BETA1A INTERFERON;

ADULT; ARTICLE; EMOTION; GAIT DISORDER; GERMANY; HEALTH CARE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; QUALITY OF LIFE; RELAPSE;

EID: 0037799553     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-002-1446-5     Document Type: Article

References (30)

1. Arnoldus JH, Killestein J, Pfennings LE et al. (2000) Quality of life during the first 6 months of interferon-beta treatment in patients with MS. Mult Scler 6: 338-342
2. Bullinger M (1995) German translation and psychometric testing of the SF-36 health survey: preliminary results from the IQOLA project. Soc Sci Med 41: 1359-1366
3. Cella DF, Dineen K, Arnason B et al. (1996) Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology 47: 129-139
4. Collegium Internationale Psychiatriae Scalarum (ed) (1981) Internationale Skalen für Psychiatrie. Beltz, Weinheim
5. Forbes RB, Lees A, Waugh N, Swingler RJ (1999) Population-based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis. BMJ 319 (7224): 1529-1533
6. Freeman JA, Langdon DW, Hobart JC, Thompson AJ (1999) Inpatient rehabilitation in multiple sclerosis: do the benefits carry over into the community? Neurology 52: 50-56
7. Freeman J, Hobart JC, Langdon DW, Thompson AJ (2000) Clinical appropriateness: a key factor in outcome measure selection. The 36 item short form health survey in multiple sclerosis. J Neurol Neurosurg Psych 68: 150-156
8. Freeman JA, Hobart JC, Thompson AJ (2001) Does adding MS-specific items to a generic measure (the SF-36) improve measurement? Neurology 57: 68-74
9. Freeman JA, Thompson AJ, Fitzpatrick et al. (2001) Interferon beta 1b in the treatment of secondary progressive MS: impact on quality of life. Neurology 57: 1870-75
10. Haupts M, Hardt C, Pöhlau D et al. (2001) Quality of life as predictor for change in disability in MS. Neurology 56: 1250
11. Hermann BP, Vickrey B, Hays RD et al. (1996) A comparison of health-related quality of life in patients with epilepsy, diabetes and multiple sclerosis. Epilepsy Res 25: 113-118
12. Hobart JC, Lamping D, Fitzpatrick R (2001) The Multiple Sclerosis Impact Scale (MSIS-29). A new patient-based outcome measure. Brain 124: 962-973
13. Kobelt G, Lindgren P, Smala A et al. (2001) Kosten und Lebensqualität bei Multipler Sklerose: eine empirische Studie in Deutschland. HEPAC 2: 60-68
14. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis. An expanded disability status scale (EDSS). Neurology 33: 1444-1452
15. Miller DM, Rudick RA, Cutter G et al. (2000) Clinical significance of the multiple sclerosis functional composite: relationship to patientreported quality of life. Arch Neurol 57: 1319-1324
16. Murphy N, Confavreux C, Haas J et al. (1998) Quality of life in multiple sclerosis in France, Germany, and the United Kingdom. J Neurol Neurosurg Psychiatry 65: 460-466
17. Nortvedt MW, Riise T, Kjell-Morten M, Nyland HI (1999) Quality of life in multiple sclerosis. Measuring the disease effects more broadly. Neurology 53: 1098-1110
18. Nortvedt MW, Riise T, Kjell-Morten M, Nyland HI (2000) Quality of life as predictor for change in disability in MS. Neurology 55: 51-54
19. O'Connor P, Lee L, Tin P et al. (2001) Determinants of overall quality of life in secondary progressive MS: A longitudinal study. Neurology 57: 889-891
20. Pfennings L, Cohen L, Miller D et al. (1999) Using the Short Form-36 with multiple sclerosis patients in five countries: a cross-cultural comparison. Psychol Rep 85: 19-31
21. Pfennings L, Cohen L, Ader H et al. (1999) Exploring differences between subgroups of multiple sclerosis patients in health-related quality of life. J Neurol 246: 587-591
22. Pöhlau D, Haupts M, Elias W et al. (1997) Production of (neutralizing) antibodies in relapsing-remitting multiple sclerosis (MS) patients treated with Interferon-beta 1a - outline of the MASTER study. Mult Scler 3: 343
23. Riazi A, Hobart JC, Lamping DL et al. (2001) Socio-demographic predictors of health-related quality of life in multiple sclerosis and comparisons with other populations. Mult Scler 7 [Suppl 1]: 378
24. Rothwell PM, McDowell Z, Wong CK, Dorman PJ (1997) Doctors and patients don't agree: cross sectional study of patients'and doctors'perceptions and assessments of disability in multiple sclerosis. BMJ 314(7094): 1580-1583
25. Schilli M, Miltenburger C, Haas J et al. (2001) Interferon beta-1b (Betaferon) maintains quality of life in MS-patients: interim analysis of an observational study. Mult Scler 7 [Suppl 1]: 112
26. Schwartz CE, Coulthard-Morris L, Cole B, Vollmer T (1997) The quality-of-life effects of interferon beta-1b in multiple sclerosis. An extended Q-TWiST analysis. Arch Neurol 54: 1475-1480
27. Solari A, Filippini G, Gasco P et al. (1999) Physical rehabilitation has a positive effect on disability in multiple sclerosis patients. Neurology 52: 57-62
28. The Canadian Burden of Illness Study Group (1998) Burden of illness of multiple sclerosis: part II: quality of life, Can J Neurol Sci 25: 31-38
29. Vickrey B (1995) A health-related quality of life measure for multiple sclerosis. Qual Life Res 4: 187-200
30. Ware JE, Sherbourne CD (1992) The MOS 36item short-form health survey (SF-36). Conceptual framework and item selection. Med Care 30: 473-483